A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Imipenem and Cilastatin (Imipenem and Cilastatin)

Penem Antibacterial class · 2 generic manufacturers · 3 ANDAs filed at FDA.

First FDA approval1985-11-26
Generic availableYes · 2 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
44 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema8 entries indexed · 4 visible
What is Imipenem and Cilastatin used for?

Imipenem and Cilastatin is a Penem Antibacterial medication tracked in Medicare Part D.

Is there a generic for Imipenem and Cilastatin?

Yes. 3 ANDAs filed at FDA, 2 generic manufacturers currently shipping.

How much does my plan pay for Imipenem and Cilastatin?

NADAC pricing data not currently available for this drug.

Is Imipenem and Cilastatin on the FDA shortage list?

Imipenem and Cilastatin has been discontinued by its manufacturer(s).

4 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Penem Antibacterial2 alternatives in D1
01
Ertapenem
Brand: ERTAPENEM
$26.83Lowest NADAC
5Generic mfrs
$108.0MCY24 Part D spend
Compare →
02
Meropenem
Penem Antibacterial
$5.84Lowest NADAC
8Generic mfrs
$26.3MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (4 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.